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Abstract
Objective: To determine if kidney function level and its rate of decline in the immediate pre-
dialysis period among veterans transitioning to end-stage renal disease (ESRD) predicts post-
dialysis mortality and hospitalization.
Patients and Methods: In 19,985 veterans transitioning to ESRD during 10/1/2007–
03/30/2014, we examined kidney function and its slope over the final year of the prelude period. 
Two categories of low versus high estimated glomerular filtration rate (eGFR, dichotomized at 10 
mL/min/1.73m2) and slow versus fast slope (dichotomized at −10 mL/min/1.73m2/year) were 
combined into four groups. Their associations with 12-month post-ESRD all-cause and 
cardiovascular (CV) mortality and hospitalization rates were examined in adjusted models 
accounting for clinical characteristics and laboratory measurements at transition.
Results: Patients, 66±11 years old, and 34% blacks, had a median[IQR] eGFR at transition and 
slope of 9.7[7.1,13.3] mL/min/1.73m2 and −10.5[−18.8,−5.9] mL/min/1.73m2/year, respectively. 
Patients with a low eGFR and slow slope, had the lowest risk of 12-month all-cause and CV 
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mortality, and hospitalization rate. Conversely, patients with high eGFR and fast slope had the 
highest risk of all-cause and CV mortality and hospitalization rate compared to patients with a low 
eGFR and slow slope. This relationship persisted in sensitivity analyses, including propensity 
scoring.
Conclusions: A kidney profile of a low eGFR and slow slope in the prelude period is associated 
with favorable early dialysis outcomes in veteran patients. Trials to examine a more conservative 
approach to dialysis are warranted.
Keywords
Conservative management; transition of care in CKD; prelude; vintage; mortality; hospitalization; 
estimated glomerular filtration rate; disease progression; veterans
Introduction
Over 120,000 persons transition to end-stage renal disease (ESRD) each year in the US, 
mostly with dialysis.1,2Mortality rates for dialysis patients are especially high in the first 
months after transition and a study investigating nursing home patients suggested that 
functionality in this early post-transition period was also substantially reduced.2,3 Thus, 
discussions have emerged pertaining to the benefit of early initiation of dialysis therapy in 
older persons, especially those with slower progressing kidney disease. Ironically, estimated 
glomerular filtration rate (eGFR) at the time of transition has progressively become higher, 
indicating a trend toward earlier transition, or a more aggressive dialysis initiation. As of 
2014, the US average eGFR at initiation was 10.2 mL/min/1.73m2.1 Despite these trends, the 
optimal timing of ESRD transition still remains controversial. Although some studies and 
clinical guidelines have previously suggested that early initiation may be beneficial,4–9 a 
clinical trial and other observational studies have suggested otherwise.10–15 However, many 
of the latter studies were limited in data on the rate of disease progression and laboratory 
measures from the period prior to transition, which are important drivers of eGFR levels at 
transition.16 As single eGFR and its slopes have become more readily available in clinical 
practice,17 it may be of importance to examine the use of both metrics in risk prediction.
In addition to the controversy of ESRD timing in the US population, it is uncertain if this is 
externally valid for the US veteran population. The veteran population comprise of 
predominately older males with likely different ailments compared to that of the greater US 
population. Preliminary data from United States Renal Data System (USRDS) “Transition-
of-Care-in-CKD” Special Study Center have shown that 11% of incident US ESRD patients 
each year are veterans, and that high mortality rates in the first months after transition also 
exist in this veteran population.1,2 Moreover, it was suggested that veterans initiating ESRD 
with a Veterans Affairs (VA) healthcare provider may have better survival, and a lower 
probability of initiating at a higher eGFR, compared to those initiating with a non-VA 
provider.1,2,18 Finally, a study investigating solely eGFR slope in the veteran population 
showed that a rapid decline was associated with higher long-term post-ERSD mortality.19
However, no study has examined whether veterans who transition to ESRD with both a 
lower eGFR and a less progressive disease, have better or worse early post-ESRD outcomes. 
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We sought to examine these outcomes in a contemporary cohort of US veteran patients 
transitioning to ESRD and hypothesized that the combination of a slower disease 
progression and lower kidney function level upon transition is associated with better 
immediate post-ESRD outcomes.
Methods
Study Population and Data Source
We retrospectively analyzed data from the Transition-of-Care-in-CKD study, which 
investigates veterans transitioning to ESRD between October 1, 2007 and March 30, 2014.1 
The source population comprised 85,505 veterans identified from the USRDS. We excluded 
1958 patients for missing follow-up information, 32,280 patients with missing data on VA 
measured serum creatinine, and 29,724 with no available creatinine measurement within 31 
days prior to transition. To calculate eGFR slope using a mixed effects regression model 
during the 12 months prior to ESRD, we further required that these patients have at least two 
eGFR measurements (including a measure within 31 days before transition) and over 30 
days apart. After excluding patients without these criteria, and slope outliers at 0.5 and 99.5 
percentiles, our final cohort comprised 19,985 veterans with both 31-day measured pre-
ESRD (prelude) eGFR and 12-month prelude eGFR slope (Supplemental Figure 1).
This study was approved by the Institutional Review Boards of the Memphis and Long 
Beach Veterans Affairs Medical Centers. Due to the large sample size, patient anonymity, 
and nonintrusive nature of the research, the written consent requirement was exempt.
Demographic, Clinical and Laboratory Measurements
Data from three national databases: USRDS, VA and Centers for Medicare and Medicaid 
Services (CMS) were combined to determine baseline characteristics. Marital status was 
obtained from VA records. Receipt of pre-ESRD care was obtained from USRDS records of 
the CMS 2728 Medical Evidence Form. Pre-existing comorbidity information was extracted 
from VA and CMS datasets using International Classification of Diseases, Ninth Revision 
(ICD-9) Diagnostic and Current Procedural Terminology codes. Charlson comorbidity index 
was calculated without renal disease. Presence of a comorbidity was assigned using a one 
inpatient or two outpatient visits algorithm.
Prelude laboratory measurements were sourced from VA databases only. Data on serum 
creatinine and other laboratory measurments were obtained from the VA Corporate Data 
Warehouse LabChem and Decision Support System National Data Extracts Laboratory 
Results files, respectively. Data on body mass index (BMI) and blood pressure were 
obtained from the VA Corporate Data Warehouse Vital Signs file. The closest measurement 
to transition within 31 days prelude period was used in analyses as baseline values.
Exposure Measurement
The primary exposure was the combination of 31-day prelude eGFR and rate of kidney 
function change in the 12-month prelude period. eGFR was calculated with the Chronic 
Kidney Disease Epidemiology Collaboration equation.20 Based on the approximate median 
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of the cohort and previous studies,11,12,19 eGFR was dichotomized as: <10 and ≥10 mL/min/
1.73m2 to represent low and high eGFR at transition, respectively. Disease progression 
(slope) was calculated using mixed effects linear regression to ascertain the annual eGFR 
slope prior to transition. Based on the approximate median of the cohort and prior study,19 
slopes were dichotomized as: >−10 and ≤−10 mL/min/1.73m2/year to represent slow and 
fast eGFR slope, respectively. A total of four combined groups (2×2) were created as our 
primary exposure, with a low 31-day eGFR and a slow 12-month eGFR slope group as the 
reference.
Outcome Assessment
The outcomes of interest were 12-month all-cause mortality, 12-month cardiovascular (CV) 
mortality, and 12-month hospitalization rate after transition. Cardiovascular reasons for 
death were obtained from the USRDS. Data on all-cause events, including death and 
hospitalizations were sourced from VA, CMS and USRDS datasets. Patients were followed 
from the start of ESRD until death, kidney transplantation, lost to follow-up, end of the 12-
month follow-up period, or September 2, 2014, whichever occurred first. For CV mortality, 
the last date of follow-up was June 30, 2014.
Statistical Analysis
Baseline patient characteristics were described as proportion, mean ± standard deviation or 
median [interquartile range, IQR], and differences across eGFR groups were compared with 
tests of chi-square, ANOVA or Kruskal-Wallis, where appropriate.
Predictors of a low eGFR and slow slope (reference= all other kidney profiles), higher eGFR 
(reference= low eGFR), and faster disease progression (reference= slow slope) were 
examined using logistic regression.
The relationship of the combination of eGFR and slope with 12-month all-cause or CV 
mortality was examined using Cox proportional hazard models. To evaluate the association 
of the combined eGFR and slope groups with 12-month hospitalization incidence rate, 
Poisson and negative binomial regression models were used.
For each outcome, three models of adjustment were used: (i) unadjusted model; (ii) case-
mix adjusted model that included the time interval between the last eGFR measurement and 
transition date, age, gender, race, ethnicity, incidence year, marital status, Charlson 
comorbidity index, diabetes, ischemic heart disease (ISHD), myocardial infarction, 
congestive heart failure (CHF), cerebrovascular disease and chronic obstructive pulmonary 
disease (COPD); and (iii) case-mix+MICS (malnutrition-inflammation cachexia syndrome) 
adjusted model which included case-mix model variables and baseline measurements of 
bicarbonate, blood urea nitrogen (BUN), hemoglobin, albumin, phosphorus, calcium, 
potassium, BMI, and systolic and diastolic blood pressure.
Sensitivity Analyses
We conducted sensitivity analyses to examine the robustness of the observed associations. 
The eGFR and slope-mortality association was evaluated across strata of clinical 
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characteristics. Wald tests for interaction were performed in the fully adjusted models. As 
fluctuations in eGFR may occur, a subgroup of 5285 patients were excluded if hospitalized 
within the 12-month prelude period with a primary diagnosis of an acute kidney injury 
(AKI) (ICD-9 code 584 or 586), or were indicated as recovered renal function by the 
USRDS within 60 days from transition.
Next, we examined additional categorizations of combined eGFR and slope. We examined 
granular groups guided by approximate quartiles of the cohort. A total of 16 groups were 
created, representing eGFR (<7, 7-<10, 10-<13 and ≥13 mL/min/1.73m2) and slope (>−5, 
−5->−10,−10−>−15, and ≤−15 mL/min/1.73m2/year).
Additionally, we also calculated percentile ranks (value 1–100) for eGFR and slope, 
respectively. A low percentile would represent a lower eGFR or slower slope, and a high 
percentile would represent a higher eGFR or faster slope. These percentiles were summed 
together (eGFR percentile plus slope percentile) or subtracted from each other (eGFR 
percentile minus slope percentile) and their respective association with all-cause mortality 
was evaluated using restricted cubic splines.
Finally, we calculated propensity scores to account for patient differences. For propensity 
score models, we examined associations of: 1) eGFR and included eGFR slope as a 
covariate and 2) eGFR slope with eGFR as a covariate. We used the propensity score in 
multiple analyses, including the propensity score in covariate adjustment, stratification based 
on propensity score tertiles, and finally, matching by propensity score.21
Data for demographics was missing for <0.15% and were imputed using a missing category. 
Laboratory variables were missing on average 11% and were imputed by means. Analyses 
were conducted using SAS Enterprise Guide (7.1) (Cary, NC), and Stata/MP Version 14 
(College Station, TX).
Results
Baseline clinical characteristics stratified by eGFR and slope groups are presented in Table 
1. The cohort was 66±11 years, and included 2% females and 34% blacks. The median 
[IQR] of eGFR at transition and slope was 9.7[7.1, 13.3] mL/min/1.73m2 and −10.5[−18.8, 
−5.9] mL/min/1.73m2/year, respectively. In our cohort, 26% of patients transitioned to 
ESRD with a low eGFR and slow slope and were more likely to be black, have pre-ESRD 
nephrology and dietician care, and had a lower prevalence of diabetes, depression, and 
COPD.
Predictors of a low eGFR and slow eGFR Slope
In adjusted analyses, compared to all other disease profiles, black race and higher albumin 
were associated with higher odds of initiating with a low eGFR and slow slope 
(OR[95%CI]: 1.51[1.39, 1.63] and 1.83[1.72, 1.96], respectively , Table 2). Conversely, in 
both unadjusted and fully adjusted models, presence of CHF was associated with lower odds 
of transitioning with a low eGFR and slow slope (OR[95%CI]: 0.60[0.56, 0.64] and 
0.77[0.71, 0.84], respectively).
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Predictors of a high eGFR or fast eGFR Slope
Among all patients who met eGFR criteria (n=21,543), presence of CHF consistently had 
the highest odds of transitioning with a high eGFR across all models (Supplemental Table 
1A). Conversely, in the fully adjusted model, predictors of lower eGFR included female sex, 
black race, Hispanic ethnicity, cerebrovascular disease, and higher albumin, BUN, and 
phosphorus.
In our analytical cohort, predictors of a faster slope included higher eGFR, hospitalization at 
transition, Charlson comorbidity index, and COPD across all models (Supplemental Table 
1B). Negative predictors of a faster slope included age, black race, ISHD, and higher 
hemoglobin. Higher albumin was associated with the lowest odds of a fast slope (OR 
[95%CI]: 0.49[0.46,0.52] after full adjustment).
Association of eGFR and Slope with 12-Month Mortality
Over a median follow-up of 366 days, 3945 deaths occurred, yielding a crude all-cause death 
rate of 23.1 per 100 patient-years [95%CI: 22.4, 23.8]. Patients with a low eGFR and slow 
slope had the lowest death rate of 13.8 per 100 patient-years [95%CI: 12.8, 14.9].
In unadjusted analyses, a low eGFR and slow slope was associated with the lowest risk of 
12-month all-cause and CV mortality (Figure 1A and 1B). After additional levels of 
adjustments, this relationship still persisted, as a low eGFR and slow slope was associated 
with the lowest risk of 12-month all-cause and CV mortality, although slightly attenuated 
with CV mortality. The greatest eGFR and fastest slope was associated with the highest risks 
of 12-month all-cause and CV mortality (HR [95% CI]: 1.80 [1.62, 1.99] and 1.57 [1.32, 
1.88], respectively in fully adjusted models) compared patients with a low eGFR and slow 
slope. Associations were similar in sensitivity analyses when excluding patients with an AKI 
or recovered function, and examining more granular groups. Patients with the highest eGFR 
at transition (≥13 mL/min/1.73m2), and fastest slope (≤−15 mL/min/1.73m2/year), had the 
highest risk of both 12-month all-cause and CV mortality across all levels of adjustment 
(Supplemental Table 2A and 2B).
Likewise, we observed that a low eGFR and slow slope was associated with lower mortality 
risk in the fully adjusted models across most strata of clinical characteristics, including race/
ethnicity and BMI. The hazard ratios for eGFR and slope groups across most strata were 
similar to that of the association observed in all patients, further confirming the robustness of 
our observed results (Supplemental Figure 2). However, there was significant effect 
modification by initial modality (P-interaction=.03). Among initial peritoneal dialysis (PD) 
patients (<5%) with an aggressive disease profile we observed a 45% lower risk of mortality 
after fully adjustment though not significant (HR [95%CI]: 0.55[0.22, 1.37]). There was 
significant interaction in eGFR and slope groups with a number of comorbidities: diabetes, 
ISHD, MI, and CHF. Similar to that of the overall cohort, a low eGFR and slow slope was 
also associated with the lowest CV mortality risk across most subgroups (Supplemental 
Figure 3). However, many of the observed relationships across strata were largely attenuated 
due to a small number of events and sample size.
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We also used the eGFR and slope composite sum or difference score to evaluate the 
combined effect. In summed rank variables, there was a linear association with 12-month 
all-cause mortality after full adjustment, where patients with a low eGFR and slow slope had 
the lowest risk for mortality (reference=100; Figure 2A). When examining the difference in 
percentile ranks, we observed a U-shaped association with 12-month all-cause mortality. 
Patients with either a low eGFR and fast slope, or high eGFR and slow slope had the highest 
adjusted risks of all-cause mortality compared to the reference of 0 (patients with either 
combination of low eGFR and slow slope, or high eGFR and fast slope) (Figure 2B).
Propensity Score Sensitivity Analyses
To account for characteristic differences, we calculated propensity scores of transitioning to 
ESRD with a high or low eGFR (Supplemental Table 3A). After matching, higher eGFR was 
associated with approximately 30% higher risk of 12-month all-cause mortality among 
12,532 matched patients after across all levels of adjustment (Table 3A). Among the 
analytical cohort, additional propensity score analyses resulted in similar findings under all 
models. Likewise, we calculated propensity scores of transitioning to ESRD with a slow or 
fast eGFR slope (Supplemental Table 3B). In this matched cohort (n=16,482), a faster slope 
was associated with a higher risk of all-cause mortality (HR[95%CI]: 1.35[1.25, 1.45], Table 
3B). Similar findings were observed in the full cohort with additional propensity 
scoreanalyses.
Association of eGFR and Slope and Hospitalization Rates
Finally, we examined the relationship of eGFR and slope with 12-month hospitalization 
incidence rate. Patients experienced a median [IQR] of 1[0, 3] hospitalizations over the early 
ESRD period. In all adjustments, we observed that a low eGFR and slow slope was 
associated with a lower hospitalization incidence rate (Figure 3). Similar to mortality 
analyses, patients with an aggressive disease profile had the highest 12-month 
hospitalization rate (IRR [95% CI]: 1.39[1.34, 1.44]) after full adjustment. The observed 
associations were similar in sensitivity analyses, including when modeled with negative 
binomial regression, excluding patients for an AKI or recovered function, and under more 
granular groups of eGFR at transition and slope (Supplemental Table 2C).
Discussion
In a contemporary cohort of 19,985 veterans who transitioned to ESRD, the combination of 
a lower kidney function with slower kidney disease progression, or low eGFR and slow 
slope, was associated with better early ESRD outcomes including lower all-cause and 
cardiovascular mortality risk and hospitalizations. The kidney disease profile of higher 
eGFR combined with fastest disease progression was associated with the highest risk of 12-
month morbidity and mortality outcomes. These relationships remained robust in sensitivity 
analyses including propensity scores, which may mitigate the likelihood of selection bias 
upon transition to ESRD.
Previous studies investigating US population cohorts have primarily relied on eGFR at 
transition,10–14 and have been limited in examining confounding due to nutritional status,16 
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especially from prior to transition, including slopes. Similar to past studies, we also 
observed higher mortality risk among patients with higher eGFR at transition, but after 
additionally accounting for eGFR slope, nutritional parameters and propensity for earlier 
transition. Many studies have demonstrated higher mortality risk with eGFR slope in many 
populations, including the community, elderly and early stage CKD patients.22–26 However, 
few studies have examined pre-ESRD eGFR trajectories and post-ESRD mortality.19,27 
O’Hare et al., showed that a catastrophic loss of eGFR was associated with the highest risk 
of 1-year all-cause mortality, yet not in longer periods of follow-up (2–5 years).27 We 
observed similar findings, in that an aggressive kidney disease profile including a fast slope 
was associated with higher early mortality risk. Additionally, Sumida et al., examined the 
eGFR slope-mortality association, with effect modification by last eGFR prior to transition.
19
 The authors found that among patients with a last eGFR≥10mL/min/1.73m2, a rapid loss 
was not associated with higher mortality risk (reference: slow decline [< −5 mL/min/1.73m2/
year]). We, however, did observe lower early mortality risk for patients initiating with a low 
eGFR and slow slope. In addition to differences in reference groups, we evaluated early 
mortality, whereas Sumida et al., examined long-term follow-up (median: 2 years),19 and it 
is possible that the eGFR slope-mortality association among patients with a high eGFR at 
transition may be impacted by time-varying dialysis treatment covariates1,28 and thus 
mitigating the long-term mortality risk.
It has been suggested that early initiators may lose renal function faster compared to later 
initiators as a repercussion of dialysis treatment especially in the early months post-
transition with thrice-weekly hemodialysis as compared to incremental hemodialysis.11,29 
Dialysis may more strongly effect early initiators, thereby more rapidly losing residual renal 
function, and experiencing inflammation, cachexia, and body mass loss, which have been 
noted as predictors of mortality risk among incident ESRD patients.11,30–32 Furthermore, 
decline in kidney function may be an indicator for other underlying conditions including 
atherosclerosis, oxidative stress, malnutrition and other cardiovascular diseases, which can 
contribute to higher morbidity and mortality.19
The lowest mortality risk, observed in patients with a low eGFR and slow slopw, may 
actually be indicative of better pre-ESRD care. Indeed, 80% and 31% of these patients had 
pre-ESRD nephrology and dietician care, respectively, compared to markedly less in other 
groups. Similar to observed trends in a previous study,27 the patients with a low eGFR and 
slow slope at initiation were less likely to initiate in a hospital and had fewer pre-ESRD 
hospitalizations. Thus, these patients may have had a better management of healthcare, 
including closer monitoring of disease progression and a planned, or maybe delayed 
transition at a lower eGFR level. These high levels of care may be carried through post-
ESRD, such that these patients may less likely to be hospitalized and have a lower mortality 
risk after transition to ESRD. Thus together, both eGFR and disease progression in 
combination, are important risk factors in post-ESRD morbidity and mortality, and eGFR 
alone may no longer be a sole factor when transitioning to ESRD.17,23 These data may have 
clinical and public health implications it suggests that a low eGFR and slow slope in the 
immediate prelude period is associated with more favorable early ESRD outcomes. It is 
suggestive that delaying transition until a lower eGFR among patients with either degree of 
slope may afford better outcomes, including a lesser life burden from time on dialysis.
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This study should be qualified for several potential limitations. Due to the observational 
nature of the study design, residual confounding cannot be completely excluded, nor can 
causal relationship be implied. An inherent limitation is confounding by indication, where 
patients with a given eGFR at transition may have other symptoms that would prompt 
transition to ESRD. While we found similar associations in sensitivity analyses when 
excluding AKI patients, this may not completely capture patients as one needed to be 
primarily diagnosed with an AKI. Thus it is possible that late stage chronic kidney disease 
patients may have had an AKI event that went unnoticed, or not identified as a primary 
diagnosis. We adjusted for nutritional parameters which although did not strongly attenuate 
observed associations, it is possible that these markers are on the causal pathway and 
covariate inclusion may be over adjustment. We adjusted for available confounders; however 
markers of renal function such as iothalamate or iohexol clearances, or muscle mass were 
unavailable. We only included patients with a measured serum creatinine 31 days prior to 
ESRD transition and met slope criteria, representing a select group of veterans who may be a 
more frequent user of VA services, however less than 10% of patients were excluded for not 
meeting slope criteria. In addition, there is survivor bias, as patients may have died before 
reaching ESRD, and thus were not an incident ESRD patient. Finally, given the composition 
of the VA population (almost 95% male), these findings may not be externally valid to other 
populations. But, our study strengths include the use and availability of combined data from 
VA, USRDS and CMS records, including repeated laboratory measures, which has often 
been missing in cohort studies. Furthermore, we used the Chronic Kidney Disease 
Epidemiology Collaboration formula in our eGFR calculation opposed the Modification of 
Diet in Renal Disease Study formula. Studies have suggested that the latter equation does 
not accurately estimate eGFR, which may lead to “greater” eGFR during initiation.12,33 
Finally, we used a linear mixed-effects regression model when calculating eGFR slope 
which may be superior in estimating change,34 compared to examining a change in percent 
or eGFR category.17 To our knowledge, this is one of the largest studies to investigate both 
ESRD timing and disease progression with early ESRD mortality and morbidity in US 
veterans.
Conclusion
In conclusion, we observed that in veteran patients transitioning to ESRD, transitioning with 
a low eGFR and slow slope was associated with lower risk of 12-month mortality and 
hospitalization, and this relationship was independent of laboratory markers. This 
relationship remained consistent across numerous sensitivity analyses. Together, these 
results further support the notion that an early transition to dialysis may not be as beneficial 
as once thought and additional studies are warranted to clarify this relationship.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Association of combined 31-day prelude eGFR and 12-month eGFR slope with 12-month 
A) all-cause mortality and b) cardiovascular mortality*
*eGFR; estimated glomerular filtration rate
Soohoo et al. Page 13
Mayo Clin Proc. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Case-mix+MICS adjusted restricted cubic splines of the A)sum and B)difference in 
percentiles of eGFR and slope with 12-month all-cause mortality*
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Figure 3. 
Association of combined 31-day prelude eGFR and 12-month eGFR slope with 12- month 
Hospitalization Incidence Rate Ratio*
Soohoo et al. Page 15
Mayo Clin Proc. Author manuscript; available in PMC 2019 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Soohoo et al. Page 16
Table 1.
Baseline characteristics of 19,985 patients stratified by eGFR at transition and eGFR slope among veterans 
who transitioned to ESRD based on thresholds as eGFR 10 mL/min/1.73m2 and eGFR slope of −10 mL/min/
1.73m2/yeara,b
eGFR at Transition and Slope
Total Low eGFR/Slow Slope
High eGFR/
Slow Slope
Low eGFR/
Fast Slope
High eGFR/
Fast Slope
N, % 19,985 5,204(26.0) 4,318 (21.6) 5,323(26.6) 5,140(25.7)
eGFR (mL/min/1.73
m2)
9.7
[7.1,13.3]
7.3
[5.8,8.6]
13.2
[11.4,16.2]
7.2
[5.7,8.6]
14
[11.7,18.5]
eGFR slope
(mL/min/1.73
m2/year)
−10.5
[−18.8,−5.9]
−5.8
[−7.9,−3.8]
−5.6
[−7.7,−3.3]
−17.3
[−29,−12.9]
−19.1
[−31,−13.4]
Days between eGFR
measurement and
transition
−1[−9,0] −−1[−8,0] −3[−13,0] 0[−3,0] −3[−14,0]
Age (years) 66±11 67±11 68±10 65±11 66±11
Gender (%)
 Female 2 3 2 3 2
Race (%)
 White 61 55 67 57 65
 Black 34 39 29 37 29
 Other 5 5 4 6 5
Ethnicity (%)
 Hispanic 8 9 7 9 8
Marital Status (%)
 Married 49 50 53 45 49
Hospitalization
Initiated in Hospital 57 50 50 66 60
Count in 6 month
prelude 1[0,2] 1[0,2] 1[1,2] 1[1,2] 2[1,3]
Pre-ESRD Care
Nephrology 68 80 75 62 54
Dietician 25 31 27 23 18
 Charlson
comorbidity index 3[2,5] 3[2,4] 4[2,5] 3[2,5] 4[3,6]
Comorbidities (%)
 Diabetes 71 67 75 68 75
 Anemia 69 76 76 61 65
 Atrial Fibrillation 12 8 16 9 16
 Depression 28 24 28 28 31
 ISHD 50 44 60 41 56
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eGFR at Transition and Slope
Total Low eGFR/Slow Slope
High eGFR/
Slow Slope
Low eGFR/
Fast Slope
High eGFR/
Fast Slope
 MI 19 15 25 15 24
 CHF 48 38 57 40 57
 PVD 32 27 37 27 36
 Cerebrovascular
Disease 25 23 30 23 27
 Dementia 2 2 2 2 2
 COPD 35 27 41 31 43
Paraplegia/Hemiplegia 3 2 3 3 3
Laboratory
measurements in
31-day prelude
 CO2 (mEq/L) 22.3±4.8 21±4.4 23.7±4.4 20.9±4.7 24±4.6
 BUN(mg/dL) 73.9±30.9 86.1±27.9 62.9±26.3 84.1±30.4 60.3±28.9
 Hemoglobin (g/dL)* 9.8±4.6 9.7±1.6 10.2±1.6 9.5±1.5 10.0±1.7
 Albumin* (g/dL) 3.2±0.7 3.4±0.6 3.3±0.6 3.3±0.7 3.0±0.7
 Phosphorus (mg/dL) 5.5±1.8 6.1±1.7 4.5±1.2 6.3±1.9 4.7±1.4
 Calcium (mg/dL) 8.5±0.9 8.5±1 8.7±0.8 8.2±0.9 8.5±0.8
 iPTH (pg/mL) 250[138,415]
322
[147,526]
210
[124,338]
289
[167,464]
189
[108,313]
 Potassium (mEq/L) 4.4±0.7 4.5±0.7 4.4±0.7 4.5±0.7 4.4±0.7
 Weight (lbs) 204±51 201±47 204±52 204±51 207±53
 Body Mass Index
(kg/m2) 29.9±6.9 29.4±6.5 29.9±7 29.7±6.8 30.3±7.3
 Systolic BP (mmHg) 142±23 144±22 139±22 144±24 138±24
 Diastolic BP
(mmHg)* 74±14 74±14 71±12 76±14 73±14
a
BP; blood pressure, BUN; blood urea nitrogen, CHF; congestive heart failure, COPD; chronic obstructive pulmonary disorder, CO2; bicarbonate, 
eGFR; estimated glomerular filtration rate, iPTH; intact parathyroid hormone, ISHD; Ischemic Heart Disease; MI; myocardial infarction, PVD; 
peripheral vascular disease.
b
Data presented as proportion, mean ± standard deviation or median [interquartile range] where appropriate. Data compared between eGFR & 
slope groups with tests for chi-square, ANOVA, or Kruskal-Wallis where appropriate. P-values for all variables were <0.01 except where noted 
with *.
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Table 2.
Multivariable logistic regression based estimated odds ratios (OR) of a low eGFR and slow eGFR slope upon 
transition compared to all other eGFR and slope groups (reference)a
Unadjusted Case Mix Case Mix + MICS
Characteristic OR(95%CI) OR(95%CI) OR(95%CI)
Age (∆10 years) 1.06(1.03,1.09) 1.23(1.19,1.27) 1.21(1.16,1.25)
Female 1.22(1.00,1.50) 1.20(0.97,1.49) 1.42(1.14,1.77)
Race (Ref. White)
Black 1.39(1.30,1.49) 1.45(1.35,1.56) 1.51(1.39,1.63)
Other 1.22(1.05,1.4) 1.20(1.03,1.39) 1.31(1.12,1.53)
Ethnicity
Hispanic 1.18(1.05,1.31) 1.26(1.12,1.42) 1.29(1.14,1.46)
Incidence Year 1.05(1.03,1.07) 1.09(1.04,1.14) 1.10(1.05,1.16)
Married 1.04(0.98,1.11) 1.08(1.01,1.15) 1.04(0.97,1.11)
Initiated in Hospital 0.70(0.66,0.74) 0.72(0.67,0.77) 0.59(0.55,0.64)
Comorbidities
Charlson comorbidity
index
0.86(0.85,0.88) 0.89(0.87,0.91) 0.91(0.88,0.93)
Diabetes 0.76(0.71,0.81) 1.00(0.92,1.08) 0.95(0.87,1.04)
ISHD 0.72(0.68,0.77) 0.97(0.89,1.05) 1.00(0.92,1.09)
MI 0.66(0.60,0.72) 0.96(0.86,1.06) 0.96(0.86,1.07)
CHF 0.60(0.56,0.64) 0.77(0.72,0.83) 0.77(0.71,0.84)
Cerebrovascular
Disease
0.83(0.77,0.89) 1.07(0.99,1.17) 1.10(1.01,1.21)
COPD 0.61(0.57,0.65) 0.80(0.74,0.87) 0.85(0.78,0.93)
Laboratory Measures
CO2 (∆1 mEq/L) 0.92(0.91,0.93) 0.93(0.92,0.93) 0.96(0.95,0.97)
BUN (∆10 mg/dL) 1.19(1.17,1.2) 1.20(1.19,1.22) 1.16(1.14,1.17)
Hemoglobin (∆1 g/dL) 0.94(0.92,0.96) 0.95(0.93,0.97) 0.95(0.93,0.98)
Albumin (∆1 g/dL) 1.85(1.75,1.95) 1.86(1.76,1.97) 1.83(1.72,1.96)
Phosphorus (∆1 mg/dL) 1.26(1.23,1.29) 1.28(1.25,1.31) 1.16(1.13,1.20)
Calcium (∆1 mg/dL) 1.06(1.02,1.1) 1.09(1.05,1.13) 1.11(1.06,1.16)
Potassium (∆1 mEq/L) 1.24(1.18,1.3) 1.24(1.18,1.29) 1.00(0.95,1.06)
Body Mass Index (∆5
kg/m2)
0.94(0.92,0.97) 0.99(0.96,1.02) 0.99(0.96,1.02)
Systolic BP
(∆10 mmHg)
1.07(1.06,1.09) 1.05(1.04,1.07) 1.08(1.05,1.10)
Diastolic BP
(∆10 mmHg)
1.05(1.03,1.08) 1.01(0.99,1.04) 0.96(0.93,1.00)
a
BP; blood pressure, BUN; blood urea nitrogen, CHF; congestive heart failure, COPD; chronic obstructive pulmonary disorder, CO2; bicarbonate, 
ISHD; Ischemic Heart Disease; MI; myocardial infarction
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Table 3.
Propensity Score Analyses for matching, adjustment and tertile stratification for the association of A) high 
eGFR (ref: low eGFR) and B) fast eGFR Slope (ref: slow eGFR slope) with 12-month all-cause mortality
A)
Propensity Score Analyses Unadjusted Case Mix a Case Mix +MICS a
N P HR(95%CI) P HR(95%CI) P HR(95%CI)
Matched 12532 <.001 1.38(1.27,1.49) <.001 1.33(1.22,1.44) <.001 1.33(1.23,1.44)
Adjusted for Propensity
Score 19985 <.001 1.58(1.49,1.69) <.001 1.29(1.20,1.39) <.001 1.29(1.20,1.39)
Tertile 1 6596 <.001 1.66(1.44,1.91) <.001 1.51(1.30,1.74) <.001 1.50(1.29,1.74)
Tertile 2 6794 <.001 1.24(1.10,1.38) <.001 1.24(1.10,1.39) .002 1.20(1.07,1.35)
Tertile 3 6595 <.001 1.34(1.18,1.53) <.001 1.34(1.18,1.52) <.001 1.29(1.13,1.48)
Propensity Score Analyses Unadjusted Case Mix b Case Mix +MICS b
N P HR(95%CI) P HR(95%CI)  P HR(95%CI)
Matched 16482 <.001 1.36(1.27,1.46) <.001 1.38(1.28,1.48) <.001 1.35(1.25,1.45)
Adjusted for Propensity
Score 19985 <.001 1.53(1.43,1.63) <.001 1.34(1.25,1.43) <.001 1.34(1.25,1.43)
Tertile 1 6596 <.001 1.58(1.39,1.79) <.001 1.59(1.4,1.80) <.001 1.54(1.36,1.75)
Tertile 2 6794 <.001 1.46(1.31,1.64) <.001 1.46(1.30,1.63) <.001 1.41(1.26,1.58)
Tertile 3 6595 .01 1.14(1.03,1.27) .01 1.17(1.05,1.30) .04 1.12(1.01,1.25)
aAdjusted models additionally include eGFR slope as a covariate
bAdjusted models additionally include eGFR as a covariate
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